Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Triage May Improve Selection to Colonoscopy and Reduce the Number of Unnecessary Colonoscopies

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Helicobacter pylori Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.

Original languageEnglish
JournalCancer Investigation
Volume36
Issue number2
Pages (from-to)165-174
ISSN0735-7907
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52644778